Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study

BACKGROUND: Interferon in combination with ribavirin has been the standard of care for chronic hepatitis C virus infection (HCV) for the past few decades. However, its effect on the risk of autoimmune diseases (ADs) among patients with HCV infection remains unclear. We assessed the potential associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Shu-Ming, Yeh, Hsing-Jung, Lin, Tzu-Min, Chang, Yu-Sheng, Hsu, Hui-Ching, Shen, Yu-Chuan, Kuo, Tzu-Tung, Chen, Jin-Hua, Chen, Shu-Chuan, Chang, Chi-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585940/
https://www.ncbi.nlm.nih.gov/pubmed/36275719
http://dx.doi.org/10.3389/fimmu.2022.992819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585940/
https://www.ncbi.nlm.nih.gov/pubmed/36275719
http://dx.doi.org/10.3389/fimmu.2022.992819

Ejemplares similares